Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ishita Drugs And IndustriesBOM:524400 -1.89%72 PB Ratio is 1.88 as of Aug. 26, 2026, which is 35% above its 10-year median of 1.39. GuruFocus rates BOM:524400 with a GF Score™ of 72/100 and a GF Value™ of ₹64.82 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 917 Drug Manufacturers companies, Ishita Drugs And Industries ranks better than 51.69% on this metric.
Ishita Drugs And Industries Ltd stock PB Ratio (=1.98) is close to 3-year low of 1.83.
The historical rank and industry rank for Ishita Drugs And Industries's PB Ratio or its related term are showing as below:
BOM:524400'
s PB Ratio Range Over the Past 10 Years
Min: 0.45 Med: 1.39 Max: 2.64
Current: 1.87
During the past 13 years, Ishita Drugs And Industries's highest PB Ratio was 2.64. The lowest was 0.45. And the median was 1.39.
BOM:524400's PB Ratio is ranked better than 51.69% of 917
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs BOM:524400: 1.87
During the past 12 months, Ishita Drugs And Industries's average Book Value Per Share Growth Rate was 7.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ishita Drugs And Industries was 10.30% per year. The lowest was 3.30% per year. And the median was 7.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ishita Drugs And Industries PB Ratio Related Terms
Ishita Drugs And Industries PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ishita Drugs And Industries's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ishita Drugs And Industries PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ishita Drugs And Industries's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ishita Drugs And Industries's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ishita Drugs And Industries (BOM:524400) has a PB Ratio of 1.88 as of Aug. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ishita Drugs And Industries and its competitors. This is 35% above median its historical median of 1.39. Over the past decade, Ishita Drugs And Industries' PB Ratio has ranged from 0.45 to 2.64. According to the industry distribution chart, Ishita Drugs And Industries ranks #443 out of 917 companies in the Drug Manufacturers industry, placing it in the top 48.3%.
Is Ishita Drugs And Industries' PB Ratio too high?
Ishita Drugs And Industries' current PB Ratio of 1.88 is 35% above median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 2.64. The Drug Manufacturers industry median PB Ratio is 1.96. Ishita Drugs And Industries' value of 1.88 is 4.1% below this industry median. Based on the distribution chart, Ishita Drugs And Industries ranks #443 out of 917 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ishita Drugs And Industries has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ishita Drugs And Industries' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ishita Drugs And Industries ranks #443 out of 917 companies for PB Ratio. This puts Ishita Drugs And Industries in the upper half of its industry. The industry median PB Ratio is 1.96. Ishita Drugs And Industries' value of 1.88 is 4.1% below this benchmark. Historically, Ishita Drugs And Industries' own PB Ratio has ranged from 0.45 to 2.64 over the past decade. While the company's 10-year median is 1.39 vs. the industry median of 1.96, Ishita Drugs And Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ishita Drugs And Industries's current PB Ratio of 1.88 is 4.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ishita Drugs And Industries and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ishita Drugs And Industries's current PB Ratio is 1.88, which is 35% above median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ishita Drugs And Industries stock overvalued right now?
Based on GuruFocus' analysis, Ishita Drugs And Industries (BOM:524400) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹64.82, compared to a current price of ₹72.60 — trading 12% above its estimated fair value. The current PB Ratio is 1.88, which is 35% above median its 10-year median of 1.39 and 4.1% below the Drug Manufacturers industry median of 1.96. Ishita Drugs And Industries' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ishita Drugs And Industries (BOM:524400), the current PB Ratio is 1.88 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ishita Drugs And Industries (BOM:524400) Overvalued in 2026?
Based on GuruFocus' analysis, Ishita Drugs And Industries stock appears to be overvalued.
The current stock price of ₹72.60 is trading 12% above its estimated GF Value™ of ₹64.82.
GuruFocus considers Ishita Drugs And Industries to be Modestly Overvalued.
Key valuation signals for BOM:524400:
PB Ratio: 1.88 (35% above median its 10-year median of 1.39)
GF Value™: ₹64.82 vs. price of ₹72.60 (12% above fair value)
Industry Position: 4.1% below the Drug Manufacturers median (#443 of 917)
No single metric tells the full story. See the BOM:524400 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ishita Drugs And Industries Ltd is engaged in the business of manufacturing various APIs and drug intermediates. The company supplies its products to various pharmaceutical companies and is also being exported to various countries across the world. The company has three manufacturing facilities located in the state of Gujarat, two for APIs and drug intermediates at Ahmedabad and Surendranagar, and one for finished pharmaceutical formulations at Mehsana.
72GF Score
Get the complete analysis for BOM:524400
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524400 has been successfully added to your 
